While these studies provide valuable information on the role of sEH/COX-2 dual inhibition in preventing the development of eosinophilia and several features of AAI, future studies will focus on investigating the therapeutic effect of dual sEH/COX-2 inhibition in a model of established allergic airway disease. The gene discussed is EPHX2; the disease is Increased total eosinophil count.